Barry Hendin, MD

Expert neurologists emphasize the importance of conversations around patient lifestyle, mental health, and comorbid conditions as keys to improve care for MS.

Barry A. Hendin, MD; Regina Berkovich, MD, PhD; and Ahmed Z. Obeidat, MD, PhD, explore the role of biomarkers, precision medicine, and repair mechanisms to improve treatment of MS going forward.

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review potential use of BTK inhibitors in the treatment of MS.

A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]

A trio of experts in multiple sclerosis exchanges their thoughts on the gains that have been made in the understanding of the progressive phases of the disease. [WATCH TIME: 3 minutes]

A trio of experts in multiple sclerosis exchanges their thoughts on the importance of patient-reported outcomes in the management of patients with the disease. [WATCH TIME: 3 minutes]

Expert neurologists comment on the impact of COVID-19 on telemedicine and MS treatment selection.

Clinical implications from VELOCE, a phase 3b study examining the effect of ocrelizumab on immune responses in patients with relapsing MS.

Dr Regina Berkovich evaluates the use of mRNA COVID-19 vaccines in patients treated with high efficacy disease-modifying therapies for MS.

Barry A. Hendin, MD, reviews guidance on COVID-19 vaccines for patients with MS, including highlights from the AAN position statement.

Drs Barry A. Hendin and Regina Berkovich comment on the management and treatment of chronic smoldering inflammation with high efficacy therapies.

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review clinical implications of real-world data on the use of cladribine and other DMTs in patients with relapsing MS that were presented at ACTRIMS 2022.

Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.

Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.

Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.

Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.

Barry A. Hendin, MD, discusses innate and adaptive immunity and BTK inhibitors in the treatment of multiple sclerosis (MS).

Barry A. Hendin, MD, and Regina Berkovich, MD, PhD, provide an overview of the immune system, focusing on innate vs adaptive immunity, in the management of multiple sclerosis.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed how much a patients prognosis plays into the treatments utilized.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed the ongoing debate of when to administer high efficacy treatments throughout the MS disease progression.

The neurologist from Banner Health and chief medical officer of the MS Association of America detailed the significant changes to the state of multiple sclerosis care over the past 3 decades.

The neurologist from Banner Health and chief medical officer of the MS Association of America provided perspective on the global impact World MS Day can have on the patient and clinician community.